Imagion Biosystems Limited (IBX:ASX)
Imagion Biosystems Limited is an Australia-based is engaged in the business of research and development of medical imaging technology through its wholly owned subsidiary, Imagion Biosystems Inc. The Company is focused on the research and development of the MagSense SPMR technology. The Company's technologies include MagSense technology and PrecisionMRX nanoparticles. MagSense technology differentiates benign from malignant tumors since the antibody-conjugated nanoparticles only bind to the targeted tumor cells. MagSense instrument uses sensitive magnetic field sensors to detect the remnant magnetic relaxation of the injected nanoparticles. MagSense nanoparticles are supplied as an injectable solution and formulated to provide delivery to specific types of cancer cells. PrecisionMRX nanoparticles are characterized superparamagnetic nanoparticles. The Company serves a range of applications, including detecting cancer, monitoring therapy and detecting other diseases.